CLEVELAND, Ohio — May 4, 2026 — Leads & Copy — Abeona Therapeutics Inc. (Nasdaq: ABEO) has granted equity awards to new non-executive employees, the company announced May 1. These awards were approved according to Nasdaq Listing Rule 5635(c)(4).
On April 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to eight individuals hired by Abeona. These equity awards relate to, in the aggregate, up to 112,621 restricted shares of Abeona common stock.
One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date. The shares granted to each employee will be fully vested on the third anniversary of the Grant Date, contingent upon each employee’s continued employment with Abeona on the applicable vesting dates.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Source: Abeona Therapeutics
